This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization with Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: Insights from the SYNTAX Trial at 5-Year Follow-Up
In this manuscript the authors present a post-hoc study of the SYNTAX trial. They compare outcomes between those patients on optimal medical therapy (OMT) and non-optimal medical therapy following revascularization for complex coronary artery disease (CAD). OMT was defined as combination of at least one antiplatelet drug, statin, beta-blocker and angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB). Only one third of the patients were found to be on OMT at 5-year follow up. Lack of OMT was associated with a higher mortality and combined endpoint of death, MI and stroke. These findings reinforce the the importance of OMT use for patients with complex CAD undergoing revascularization.